adalimumab
abbvie
['axspa', ' ada ']
surpass was a head-to-head study comparing sec vs ada biosimilar (sdz-adl) in r-axspa on spinal radio progression: results showed no significant diff in spinal radio progression bet. the 2 grps. biosimilars remain tx options for r-axspa.
#acr22 abst#l15
rheumatologist. ?? ???? travelbug. geek. health professions education grad student. all these personified under perfectly shaped brows. ? tweets are my own.